You are here

Publications

Search

Show only items where

Author

Type

Term

Year

Keyword

Found 2633 results

Filters: First Letter Of Last Name is S [Clear All Filters]

2021

Bloch, J. S., Mukherjee, S., Kowal, J., Filippova, E. V., Niederer, M., Pardon, E., Steyaert, J., Kossiakoff, A. A., and Locher, K. P. (2021) Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins. Proc Natl Acad Sci U S A. 10.1073/pnas.2115435118

Mélin, L., Abdullayev, S., Fnaiche, A., Vu, V., Suárez, N. González, Zeng, H., Szewczyk, M. M., Li, F., Senisterra, G., Allali-Hassani, A., Chau, I., Dong, A., Woo, S., Annabi, B., Halabelian, L., LaPlante, S. R., Vedadi, M., Barsyte-Lovejoy, D., Santhakumar, V., and Gagnon, A. (2021) Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid. ChemMedChem. 16, 2982-3002

Mélin, L., Abdullayev, S., Fnaiche, A., Vu, V., Suárez, N. González, Zeng, H., Szewczyk, M. M., Li, F., Senisterra, G., Allali-Hassani, A., Chau, I., Dong, A., Woo, S., Annabi, B., Halabelian, L., LaPlante, S. R., Vedadi, M., Barsyte-Lovejoy, D., Santhakumar, V., and Gagnon, A. (2021) Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid. ChemMedChem. 16, 2982-3002

Mélin, L., Abdullayev, S., Fnaiche, A., Vu, V., Suárez, N. González, Zeng, H., Szewczyk, M. M., Li, F., Senisterra, G., Allali-Hassani, A., Chau, I., Dong, A., Woo, S., Annabi, B., Halabelian, L., LaPlante, S. R., Vedadi, M., Barsyte-Lovejoy, D., Santhakumar, V., and Gagnon, A. (2021) Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid. ChemMedChem. 16, 2982-3002

Mélin, L., Abdullayev, S., Fnaiche, A., Vu, V., Suárez, N. González, Zeng, H., Szewczyk, M. M., Li, F., Senisterra, G., Allali-Hassani, A., Chau, I., Dong, A., Woo, S., Annabi, B., Halabelian, L., LaPlante, S. R., Vedadi, M., Barsyte-Lovejoy, D., Santhakumar, V., and Gagnon, A. (2021) Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid. ChemMedChem. 16, 2982-3002

Ye, G., Gallant, J., Zheng, J., Massey, C., Shi, K., Tai, W., Odle, A., Vickers, M., Shang, J., Wan, Y., Du, L., Aihara, H., Perlman, S., LeBeau, A., and Li, F. (2021) The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. Elife. 10.7554/eLife.64815

Ye, G., Gallant, J., Zheng, J., Massey, C., Shi, K., Tai, W., Odle, A., Vickers, M., Shang, J., Wan, Y., Du, L., Aihara, H., Perlman, S., LeBeau, A., and Li, F. (2021) The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. Elife. 10.7554/eLife.64815

Rothenburger, T., Thomas, D., Schreiber, Y., Wratil, P. R., Pflantz, T., Knecht, K., Digianantonio, K., Temple, J., Schneider, C., Baldauf, H. - M., McLaughlin, K. - M., Rothweiler, F., Bilen, B., Farmand, S., Bojkova, D., Costa, R., Ferreirós, N., Geisslinger, G., Oellerich, T., Xiong, Y., Keppler, O. T., Wass, M. N., Michaelis, M., and Cinatl, J. (2021) Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res. 40, 317

Rothenburger, T., Thomas, D., Schreiber, Y., Wratil, P. R., Pflantz, T., Knecht, K., Digianantonio, K., Temple, J., Schneider, C., Baldauf, H. - M., McLaughlin, K. - M., Rothweiler, F., Bilen, B., Farmand, S., Bojkova, D., Costa, R., Ferreirós, N., Geisslinger, G., Oellerich, T., Xiong, Y., Keppler, O. T., Wass, M. N., Michaelis, M., and Cinatl, J. (2021) Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res. 40, 317

Ren, W., Fan, H., Grimm, S. A., Kim, J. Jin, Li, L., Guo, Y., Petell, C. James, Tan, X. - F., Zhang, Z. - M., Coan, J. P., Yin, J., Kim, D. In, Gao, L., Cai, L., Khudaverdyan, N., Çetin, B., Patel, D. J., Wang, Y., Cui, Q., Strahl, B. D., Gozani, O., Miller, K. M., O'Leary, S. E., Wade, P. A., Wang, G. Greg, and Song, J. (2021) DNMT1 reads heterochromatic H4K20me3 to reinforce LINE-1 DNA methylation. Nat Commun. 12, 2490

Ren, W., Fan, H., Grimm, S. A., Kim, J. Jin, Li, L., Guo, Y., Petell, C. James, Tan, X. - F., Zhang, Z. - M., Coan, J. P., Yin, J., Kim, D. In, Gao, L., Cai, L., Khudaverdyan, N., Çetin, B., Patel, D. J., Wang, Y., Cui, Q., Strahl, B. D., Gozani, O., Miller, K. M., O'Leary, S. E., Wade, P. A., Wang, G. Greg, and Song, J. (2021) DNMT1 reads heterochromatic H4K20me3 to reinforce LINE-1 DNA methylation. Nat Commun. 12, 2490

Swain, M., Ageeli, A. A., Kasprzak, W. K., Li, M., Miller, J. T., Sztuba-Solinska, J., Schneekloth, J. S., Koirala, D., Piccirili, J., Fraboni, A. J., Murelli, R. P., Wlodawer, A., Shapiro, B. A., Baird, N., and Le Grice, S. F. J. (2021) Dynamic bulge nucleotides in the KSHV PAN ENE triple helix provide a unique binding platform for small molecule ligands. Nucleic Acids Res. 49, 13179-13193

Swain, M., Ageeli, A. A., Kasprzak, W. K., Li, M., Miller, J. T., Sztuba-Solinska, J., Schneekloth, J. S., Koirala, D., Piccirili, J., Fraboni, A. J., Murelli, R. P., Wlodawer, A., Shapiro, B. A., Baird, N., and Le Grice, S. F. J. (2021) Dynamic bulge nucleotides in the KSHV PAN ENE triple helix provide a unique binding platform for small molecule ligands. Nucleic Acids Res. 49, 13179-13193

Swain, M., Ageeli, A. A., Kasprzak, W. K., Li, M., Miller, J. T., Sztuba-Solinska, J., Schneekloth, J. S., Koirala, D., Piccirili, J., Fraboni, A. J., Murelli, R. P., Wlodawer, A., Shapiro, B. A., Baird, N., and Le Grice, S. F. J. (2021) Dynamic bulge nucleotides in the KSHV PAN ENE triple helix provide a unique binding platform for small molecule ligands. Nucleic Acids Res. 49, 13179-13193

Swain, M., Ageeli, A. A., Kasprzak, W. K., Li, M., Miller, J. T., Sztuba-Solinska, J., Schneekloth, J. S., Koirala, D., Piccirili, J., Fraboni, A. J., Murelli, R. P., Wlodawer, A., Shapiro, B. A., Baird, N., and Le Grice, S. F. J. (2021) Dynamic bulge nucleotides in the KSHV PAN ENE triple helix provide a unique binding platform for small molecule ligands. Nucleic Acids Res. 49, 13179-13193

Duncan-Lowey, B., McNamara-Bordewick, N. K., Tal, N., Sorek, R., and Kranzusch, P. J. (2021) Effector-mediated membrane disruption controls cell death in CBASS antiphage defense. Mol Cell. 10.1016/j.molcel.2021.10.020

Sullivan, J. R., Lupien, A., Kalthoff, E., Hamela, C., Taylor, L., Munro, K. A., T Schmeing, M., Kremer, L., and Behr, M. A. (2021) Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline. PLoS Pathog. 17, e1009965

Sullivan, J. R., Lupien, A., Kalthoff, E., Hamela, C., Taylor, L., Munro, K. A., T Schmeing, M., Kremer, L., and Behr, M. A. (2021) Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline. PLoS Pathog. 17, e1009965

Samkian, A. E., Kiel, G. R., Jones, C. G., Bergman, H. M., Oktawiec, J., Nelson, H. M., and T Tilley, D. (2021) Elucidation of Diverse Solid-State Packing in a Family of Electron-Deficient Expanded Helicenes via Microcrystal Electron Diffraction (MicroED)*. Angew Chem Int Ed Engl. 60, 2493-2499

Xu, Y., Robev, D., Saha, N., Wang, B., Dalva, M. B., Xu, K., Himanen, J. P., and Nikolov, D. B. (2021) The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism. Int J Mol Sci. 10.3390/ijms221910473

Teng, M., Jiang, J., Ficarro, S. B., Seo, H. - S., Bae, J. Hyun, Donovan, K. A., Fischer, E. S., Zhang, T., Dhe-Paganon, S., Marto, J. A., and Gray, N. S. (2021) Exploring Ligand-Directed -Acyl--alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development. ACS Med Chem Lett. 12, 1302-1307

Williams, W. B., R Meyerhoff, R., Edwards, R. J., Li, H., Manne, K., Nicely, N. I., Henderson, R., Zhou, Y., Janowska, K., Mansouri, K., Gobeil, S., Evangelous, T., Hora, B., Berry, M., A Abuahmad, Y., Sprenz, J., Deyton, M., Stalls, V., Kopp, M., Hsu, A. L., Borgnia, M. J., Stewart-Jones, G. B. E., Lee, M. S., Bronkema, N., M Moody, A., Wiehe, K., Bradley, T., S Alam, M., Parks, R. J., Foulger, A., Oguin, T., Sempowski, G. D., Bonsignori, M., LaBranche, C. C., Montefiori, D. C., Seaman, M., Santra, S., Perfect, J., Francica, J. R., Lynn, G. M., Aussedat, B., Walkowicz, W. E., Laga, R., Kelsoe, G., Saunders, K. O., Fera, D., Kwong, P. D., Seder, R. A., Bartesaghi, A., Shaw, G. M., Acharya, P., and Haynes, B. F. (2021) Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 184, 2955-2972.e25

Williams, W. B., R Meyerhoff, R., Edwards, R. J., Li, H., Manne, K., Nicely, N. I., Henderson, R., Zhou, Y., Janowska, K., Mansouri, K., Gobeil, S., Evangelous, T., Hora, B., Berry, M., A Abuahmad, Y., Sprenz, J., Deyton, M., Stalls, V., Kopp, M., Hsu, A. L., Borgnia, M. J., Stewart-Jones, G. B. E., Lee, M. S., Bronkema, N., M Moody, A., Wiehe, K., Bradley, T., S Alam, M., Parks, R. J., Foulger, A., Oguin, T., Sempowski, G. D., Bonsignori, M., LaBranche, C. C., Montefiori, D. C., Seaman, M., Santra, S., Perfect, J., Francica, J. R., Lynn, G. M., Aussedat, B., Walkowicz, W. E., Laga, R., Kelsoe, G., Saunders, K. O., Fera, D., Kwong, P. D., Seder, R. A., Bartesaghi, A., Shaw, G. M., Acharya, P., and Haynes, B. F. (2021) Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 184, 2955-2972.e25

Williams, W. B., R Meyerhoff, R., Edwards, R. J., Li, H., Manne, K., Nicely, N. I., Henderson, R., Zhou, Y., Janowska, K., Mansouri, K., Gobeil, S., Evangelous, T., Hora, B., Berry, M., A Abuahmad, Y., Sprenz, J., Deyton, M., Stalls, V., Kopp, M., Hsu, A. L., Borgnia, M. J., Stewart-Jones, G. B. E., Lee, M. S., Bronkema, N., M Moody, A., Wiehe, K., Bradley, T., S Alam, M., Parks, R. J., Foulger, A., Oguin, T., Sempowski, G. D., Bonsignori, M., LaBranche, C. C., Montefiori, D. C., Seaman, M., Santra, S., Perfect, J., Francica, J. R., Lynn, G. M., Aussedat, B., Walkowicz, W. E., Laga, R., Kelsoe, G., Saunders, K. O., Fera, D., Kwong, P. D., Seder, R. A., Bartesaghi, A., Shaw, G. M., Acharya, P., and Haynes, B. F. (2021) Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 184, 2955-2972.e25

Williams, W. B., R Meyerhoff, R., Edwards, R. J., Li, H., Manne, K., Nicely, N. I., Henderson, R., Zhou, Y., Janowska, K., Mansouri, K., Gobeil, S., Evangelous, T., Hora, B., Berry, M., A Abuahmad, Y., Sprenz, J., Deyton, M., Stalls, V., Kopp, M., Hsu, A. L., Borgnia, M. J., Stewart-Jones, G. B. E., Lee, M. S., Bronkema, N., M Moody, A., Wiehe, K., Bradley, T., S Alam, M., Parks, R. J., Foulger, A., Oguin, T., Sempowski, G. D., Bonsignori, M., LaBranche, C. C., Montefiori, D. C., Seaman, M., Santra, S., Perfect, J., Francica, J. R., Lynn, G. M., Aussedat, B., Walkowicz, W. E., Laga, R., Kelsoe, G., Saunders, K. O., Fera, D., Kwong, P. D., Seder, R. A., Bartesaghi, A., Shaw, G. M., Acharya, P., and Haynes, B. F. (2021) Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 184, 2955-2972.e25

Pages

Quick Links

The Northeastern Collaborative Access Team (NE-CAT) facility at the Advanced Photon Source at Argonne National Laboratory is managed by Cornell University and consists of eight member institutions:

Columbia University
Cornell University
Genentech
Harvard University
Memorial Sloan-Kettering Cancer Center
Massachusetts Institute of Technology
Rockefeller University
Yale University

Primary funding for this project comes from the National Institute of General Medical Sciences (NIGMS), a division of the National Institutes of Health (NIH). Additional financial support for NE-CAT comes from the member institutions.